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ApoptosisThe D178N mutation of the prion protein (PrP) results in the hereditary prion disease fatal familial insomnia
(FFI). Little is known regarding the effects of methionine oxidation on the pathogenesis of D178N-associated
FFI. In the present study, we found that the D178N variant was more susceptible to oxidation than wild-type
PrP, as indicated by reverse-phase high performance liquid chromatography (RP-HPLC) and mass spectrometry
(MS) analysis. Circular dichroism (CD), differential scanning calorimetry (DSC), thioﬂavin T (ThT) binding assay
studies demonstrated that methionine oxidation decreased the structural stability of the D178N variant, and the
oxidizedD178Nvariant exhibited a greater propensity to formβ-sheet-rich oligomers and aggregates.Moreover,
these aggregates of oxidized D178N PrP were more resistant to proteinase K (PK) digestion. Additionally, using
ﬂuorescence confocal microscopy, we detected a high degree of aggregation in D178N-transfected Neuro-2a
(N2a) cells after treatmentwith hydrogen peroxide (H2O2). Furthermore, the oxidation and consequent aggrega-
tion of the D178N variant induced greater apoptosis of N2a cells, asmonitored usingﬂow cytometry. Collectively,
these observations suggest that methionine oxidation accelerates the aggregation and enhances the neurotoxic-
ity of the D178N variant, possibly providing direct evidence to link the pathogenesis of D178N-associated FFI
with methionine oxidation.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Prions are infectious pathogens that cause several invariably neuro-
degenerative diseases, including kuru, Gerstmann–Sträussler–Scheinker
disease (GSS), fatal familial insomnia (FFI), and Creutzfeldt–Jakob dis-
ease (CJD) in humans; bovine spongiform encephalopathy (BSE) in cat-
tle; and scrapie in sheep [1,2]. The conversion of normal cellular prion
protein (PrPC) into a pathological infectious isoform (PrPSc) [3] lies at
the heart of the disease pathogenesis. In contrast to the proteinase K
(PK)-sensitive, α-helical monomeric PrPC form, PrPSc is relatively resis-
tant to proteinase K digestion and possesses a β-sheet-rich structure;
moreover, PrPC is soluble in detergent, whereas PrPSc is relatively insol-
uble in most detergents in the aggregated state [4,5].lar PrP; FFI, fatal familial insom-
quidchromatography;MS,mass
on/ionization time-of-ﬂight; LC,
ss spectrometry;CD, circulardi-
semi-denaturingdetergent aga-
1-naphthalen-sulfonic acid; PK,
Virology, Wuhan Institute of
30071, China. Tel./fax: +86 27
eng@wh.iov.cn (Z. Zhou).Approximately 40 point mutations and polymorphisms in the
human PRNP gene have been linked to inherited human prion diseases,
including D178N-associated FFI. Fatal familial insomnia (FFI), which is
the third most common hereditary prion disease worldwide, was ﬁrst
reported by Lugaresi [6] and is associated with a missense mutation of
the prion protein (PrP) gene (PRNP) at codon 178 [7,8]. In a previous
study, we identiﬁed several FFI pedigrees [9] in China. Numerous stud-
ies have reported that the combination of this D178Nmutation in PRNP
with a valine encoded at position 129 resulted in one of the subtypes of
familial CJD (178CJD) [10,11]. However, the mechanism by which the
D178N mutation induces FFI remains unclear.
Numerous studies have described an association between the path-
ogenicity of neurodegenerative disorders and oxidative stress [12–17].
Previous studies found the presence of methionine (Met)-oxidized PrP
in PrPSc that was isolated from brain homogenates [18]. Canello et al.
also detected that a large fraction of the Met residues in brain PrPSc
were modiﬁed as methionine sulfoxides [19]. Recently, several studies
usingmolecular simulation or experimental Met analogs have reported
that Met oxidation may destabilize the structure of wild-type PrP and
facilitate PrPSc formation [20,21]. Based on these studies, we inferred
that methionine oxidation may play a special role in the pathogenicity
of the disease-associated D178N variant. However, the relationship be-
tween methionine oxidation of the disease-associated D178N variant
and its pathogenicity has thus far not been reported.
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in numerous proteins [21–23]. Themethionine oxidation of PrP byH2O2
has previously been characterized using mass spectrometry [20,22,24].
Here, we investigated the potential effects of methionine oxidation on
the aggregation of the FFI-associated D178N variant. Using several bio-
physical methods, we found that the D178N variant wasmore suscepti-
ble to oxidation than wild-type PrP and exhibited a greater propensity
to form β-sheet-rich oligomers and aggregates. Oxidative treatment of
N2a cells transfectedwith the D178N variant resulted in a large number
of aggregates that exhibited increased proteinase K resistance and, sub-
sequently, induced greater cell apoptosis.
2. Materials and methods
2.1. Plasmid construction and protein puriﬁcation
The plasmid construction of recombinant human PrP23-231 (huPrP)
was performed as described previously [25]. The D178N huPrP variant
was constructed by site-directed mutagenesis using a Quick Change
kit and the appropriate primers. Recombinant huPrP and D178N
huPrP variant were expressed in Escherichia coli BL21 (DE3). The inclu-
sion bodies were puriﬁed and refolded on a Ni-NTA-agarose column by
decreasing Gdn-HCl gradient concentrations as described [26]. The pu-
riﬁed protein was dialyzed overnight against 25mM sodium phosphate
buffer at pH 6.0. The concentrations of proteins were determined using
the molar extinction coefﬁcient (at 280 nm) of 57,995 M−1 cm−1. The
full-length humanPrP1-253 genewas inserted into a eukaryotic expres-
sion vector pcDNA3.1 (+) (Invitrogen, USA) using EcoRI/XholI sites.
PrP1-22 (signal peptide) and PrP23-253 were separately fused in the
pDsRed-monomer-N1 vector (Clontech, USA) using the restriction
sites EcoRI/XholI and NotI, respectively, to generate the sp-RFP-PrP for
the expression of RFP fused PrP in cells. The plasmids D178N huPrP1-
253 and D178N sp-RFP-PrP variant were also constructed by site-
directed mutagenesis using a Quick Change kit and the appropriate
primers.
2.2. Oxidation of PrP and reverse-phase HPLC analysis
Wild-type and D178N PrP were oxidized by incubation with hydro-
gen peroxide (H2O2). The concentration of PrP in the samples was
35 μM, andH2O2was added to a ﬁnal concentration of 50mM. The reac-
tion mixture was incubated at 37 °C for the indicated times. Samples
were rapidly dialyzed against 25 mM sodium phosphate buffer at
pH 6.0 to eliminate unreacted H2O2.
Reverse-phase HPLC was performed using an Agilent 1200 series
HPLC system equipped with a C8 column (3.9 × 150 mm, 5 μm,Waters,
USA). Samples of PrP oxidation reactions taken at various times were
centrifuged at 15,000 rpm for 5 min and were subsequently loaded and
eluted using a gradient beginning with solvent A (0.1% triﬂuoroacetic
acid in ddH2O) and then including an increasing percentage of
solvent B (0.1% triﬂuoroacetic acid in acetonitrile). The gradient
used was as follows: 0–10% solvent B in 5 min, 10–30% solvent B in
20 min, 30–40% solvent B in 5 min, and, ﬁnally, a return to 0% solvent
B in 5 min.
2.3. Mass spectrometry
2.3.1. MALDI-TOF mass spectrometry
Oxidized andunoxidizedD178Nandwild-type PrP sampleswere di-
alyzed overnight against 25mM sodium phosphate buffer at pH 6.0 and
then desalted using C4 ZipTips (Millipore, MA) according to the
manufacturer's protocol. Saturated sinapinic acid was used as the ma-
trix for MALDI-TOF analysis and was prepared in an aqueous solution
containing 45% acetonitrile and 0.1% triﬂuoroacetic acid. The sample
was mixed with the matrix on a ground steel target plate and allowed
to air-dry at room temperature prior to MALDI-TOF analysis. MALDI-TOF mass spectra were acquired using an UltraFlex I MALDI-TOF/TOF
mass spectrometer (Bruker Daltonics, Germany).
2.3.2. Electrospray ionization mass spectrometry (ESI-MS)
During oxidation, aliquots of D178N variant and wild-type PrP sam-
ples were removed and analyzed in 15% SDS-PAGE gels using SDS load-
ing buffer containing 4.5 M urea; the proteins were detected using
GelCodeBlue Stain Reagent (Thermo). After tryptic digestion, the peptide
mixture was desalted using C18 ZipTips (Millipore, MA) according to the
manufacturer's protocol. The extent of Methionine oxidation of oxidized
D178N PrP samples was conﬁrmed by high-resolution mass analysis
using nano-ESI-based LC–MS/MS. All nano-ESI-based LC–MS/MS experi-
ment were performed on a TripleTOF 5600+ System (AB SCIEX, Foster
City, CA) coupledwith a splitless Ultra 1D Plus (Eksigent, Dublin, CA) sys-
tem. The desalted peptides were dissolved in 0.1% formic acid/2% aceto-
nitrile/98% H2O, loaded into a C18 trap column (5 μm, 5 × 0.3 mm,
Agilent Technologies, Inc.) at a ﬂow rate of 5 μL/min, and subsequently
eluted from the trap column over the C18 analytic column 6, 9, 10
(75 μm × 150 mm, 3 μm particle size, 100 Å pore size, Eksigent) at a
ﬂow rate of 300 nL/min in a 100 min gradient. The mobile phase
consisted of two components: component A was 3% DMSO/97% H2O
with 0.1% formic acid, and component B was 3% DMSO/97% acetonitrile
with 0.1% formic acid. The IDA (information dependent acquisition)
mode was used to acquire MS/MS. Survey scans were acquired in
250 ms and 40 product ion scans were collected in 50 ms/per scan. The
precursor ion range was set fromm/z 200 to m/z 1500, and the product
ion rangewas set fromm/z 100 tom/z 1500. Tandemmass spectra were
extracted by Peakview version 2.0.
2.3.3. Analysis of MS data for protein identiﬁcation
Analysis of the raw MS spectra generated by LC–MS/MS analyses
were performed with the ProteinPilot 4.5 software program (AB SCIEX,
USA) using the Paragon algorithm. The data analysis parameters were
as follows: Sample type: Identiﬁcation; Cys Alkylation: Iodoacetamide;
Digestion: Trypsin; Instrument: TripleTOF 5600; Special Factors: Urea
denaturation; ID Focus: Biological modiﬁcations, Amino acid substitu-
tion; Search Effort: Thorough ID; Detected Protein Threshold [Unused
ProtScore (Conf)]: 1.3 (95.0%); Database: Uni-prot.
2.4. Secondary structure and thermal stability
2.4.1. CD spectroscopy
Circular dichroism spectra were obtained using a Chirascan CD spec-
trometer (Applied Photophysics, United Kingdom) using a 1-mm
pathlength cuvette at 25 °C. Far-UV CD spectra were recorded from 195
to 250 nm. A protein concentration of 10 μM was used. Each spectrum
represents an average of three scans that were corrected by subtracting
a buffer blank. The experimental results were expressed in units of
mean residue molar ellipticity (deg × cm2 × d−1) using the relationship
[θ] = θobs × MRW/(10 × l × c), whereMRW is themean residuemolecu-
lar weight, θobs is the observed ellipticity in degrees, c is the concentration
in g/ml, and l is the path length in centimeters.
Equilibrium thermal-unfolding CD analysis of protein stability was
performed at a protein concentration of 10 μM. The CD signal was moni-
tored at 222nm in the temperature range of 25–90 °Cusing aheating rate
of 1 °C/min.
2.4.2. Differential scanning calorimetry (DSC)
The thermal stabilities of unoxidized and oxidized PrP samples were
further monitored using a capillary cell Nano DSC (TA Instruments). All
experiments used 45 μM protein in 25 mM sodium phosphate buffer at
pH 6.0, and the samples were degassed prior to use. A heating rate of
1 °C/min was used, and the scanning was performed from 25 to
100 °C under nitrogen pressure. A baseline was obtained by scanning
the buffer using an identical heating rate, which was subtracted from
the experimental runs. The Tm value was obtained from curve ﬁtting
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software.
2.5. Thioﬂavin T (ThT)-binding ﬂuorescence
A 2.5 mM stock solution of ThT (Sigma-Aldrich, USA) was freshly
prepared in 25 mM sodium phosphate buffer (pH 6.0) and passed
through a 0.22-μm-pore-size ﬁlter (Millipore, USA) prior to use to re-
move insoluble particles. The assays were performed at room tempera-
ture using an F-4600 ﬂuorescence spectrophotometer (Hitachi, Japan).
Samples were incubated with 250 μM ThT for 15 min prior to analysis.
The ﬂuorescence of ThT was excited at 450 nm using a slit width of
5 nm, and the emission was collected from 470 to 530 nm using a slit
width of 10 nm. Each emission spectrum represents the average of
three scans.
2.6. 8-Anilino-1-naphthalen- sulfonic acid (ANS)-binding ﬂuorescence
A 2.5 mM stock solution of ANS (Sigma-Aldrich, USA) was freshly
prepared in 25 mM sodium phosphate buffer (pH 6.0) and passed
through a 0.22-μm-pore-size ﬁlter (Millipore, USA) prior to use to re-
move insoluble particles. The assays were performed at room tempera-
ture using an F-4600 ﬂuorescence spectrophotometer (Hitachi, Japan).
Samples were incubated with 100 μM ANS for 15 min prior to analysis.
The ﬂuorescence of ANS was excited at 380 nm using a slit width of
5 nm, and the emission was collected from 400 to 700 nm using a slit
width of 10 nm. Each emission spectrum represents the average of
three scans.
2.7. Aggregation assays
To investigate the aggregation status of oxidized PrP, nonreducing
SDS-PAGE was used to separate monomers, dimers and higher-order
aggregates. The electrophoretic mobility of the PrP samples was
assessed during oxidation using precast 4–12% NuPAGE Bis-Tris gradi-
ent gels (Invitrogen, USA). Prior to electrophoresis, each sample was
prepared in 1 × NuPAGE LDS sample buffer (26.5 mM Tris–HCl,
35.25 mM Tris base, 0.5% LDS, 2.5% glycerol, 0.1275 mM EDTA,
0.055mMSERVABlueG250, and0.04375mMphenol red, pH 8.5). Elec-
trophoresis was performed at 200 V for 70 min at room temperature in
NuPAGEMOPS SDS runningbuffer, and the resulting bandswere detect-
ed using Coomassie Brilliant Blue.
2.8. PK digestion assays
Oxidized PrP samples were dialyzed against 25 mM sodium phos-
phate buffer at pH 6.0 and were then incubated with PK at PK:PrP
molar ratios from 1:5,000 to 1:50 for 1 h at 37 °C. Digestion was
quenched using 2 mM PMSF. The samples were analyzed in 15% SDS-
PAGE gels, and protein bands were detected using Coomassie Brilliant
Blue.
To evaluate the PK resistance of samples in cells under oxidative
stress, N2a cells were transiently transfected with wild-type huPrP1-
253 and D178N plasmids; 24 h posttransfection, the cells were treated
or not treated with 50 μM H2O2 for an additional 12 h. The cell culture
lysates were then exposed to 2 μg/ml PK for 30 min at 37 °C. Western
blot analysis was probed with 1:5000 diluted anti-PrP antibody
(ab52604, Abcam) recognizing residues near the C-terminus of human
PrP.
2.9. The detection of PrP aggregation in cell
2.9.1. The detection of PrP aggregation using confocal microscopy
Cells were grown in glass-bottomed microwell dishes (MatTek,
USA). We transiently transfected RFP-fused wild-type and D178N PrPs
in Neuro-2a cells (N2a); 24 h posttransfection, the cells were treatedor not treated with 50 μM H2O2 for an additional 12 h. Thioﬂavin S
(ThS) staining was performed as described by Kimura et al. [27]. Brieﬂy
(when applicable), the cells were ﬁxed, permeabilized, and then
washed three times with G1T buffer (1% gelatin, 0.5 mg/ml bovine
serum albumin, 150 mM NaCl, 50 mM HEPES, and 0.1% Tween 20).
Thereafter, the cells were stained in 0.001% ThS for 20 min and then
washed an additional three times with G1T buffer. The samples were
dissolved in p-phenylenediamine (1 mg/ml in 90% glycerol). Image ac-
quisition was performed using an UltraVIEWVoX laser-scanning confo-
cal system (PerkinElmer, USA).
2.9.2. Semi-denaturing detergent-agarose gel electrophoresis (SDD-AGE)
Aggregation was also evaluated using SDD-AGE analysis, which has
frequently been applied in the study of prion aggregates, as previously
described [28]. The aggregation states of expressed PrP were investigat-
ed in N2a cells. N2a cells were transiently transfected with wild-type
huPrP1-253 and D178N huPrP1-253 plasmids; 24 h post transfection,
the cells were treated or not treated with 50 μMH2O2 for an additional
12 h. Cells were subsequently lysed in 50mMTris–HCl, pH 7.5, 150mM
NaCl, 1 mM EDTA, 1% Nonidet P-40, and protease inhibitor cocktail
(Calbiochem, USA), and thenwere centrifuged at 4000 g for 5min to re-
move nuclei and cell debris. Samples were incubated for 5 min in sam-
ple buffer (2 × TAE, 20% glycerol, 8% SDS, and 0.05% bromophenol blue)
and were then resolved on a horizontal agarose gel (1.5%) in TAE con-
taining 0.1% SDS. After electrophoresis for 150min at 130 V, the proteins
were transferred to a nitrocellulose membrane (Hybond ECL, GE
Healthcare). Western blot analysis was probed with 1:5000 diluted
anti-PrP antibody (ab52604, Abcam) recognizing residues near the C-
terminus of human PrP.
2.10. Apoptosis assays using ﬂow cytometry
The extent of cell apoptosis was evaluated using an Annexin V-FITC
Apoptosis Detection Kit (BenderMedSystems, Austria) and ﬂow cytom-
etry. Cells transfected with pcDNA3.1, wild-type huPrP1-253, or D178N
huPrP1-253 were grown at a density of 1 × 106/ml cells in 24-well cul-
ture dishes andwere treated with 50 μMH2O2 for 12 h. After treatment,
the cells were harvested and washed with PBS. The cells were stained
with annexin V and propidium iodide (PI) and were analyzed using
ﬂow cytometry (BD FACSAriaTM III) to assess the proportions of apopto-
tic and nonviable cells, respectively. Total apoptotic cells were deter-
mined by adding together the percentages of early and late apoptotic
cells.
3. Results
3.1. The D178N variant is more sensitive to oxidation than wild-type huPrP
Treatment of wild-type huPrP and the D178N variant with H2O2 re-
sulted in a time-dependent shift in the reverse-phase HPLC mobility of
the proteins to shorter retention times. As shown in Fig. 1A and B,
after 2-h treatmentwith H2O2, an earlier peak (B peak) with a retention
time of 21.5min appeared accompanied by the complete disappearance
of the original peaks (A peak) of unoxidized wild-type and unoxidized
D178N PrP; however, an additional peak (C peak) with a shorter reten-
tion time of 19.7minwas detected in theD178N PrP samples.When the
incubation time was extended to 8 h, most of D178N PrP eluted at
19.7 min (C peak). In contrast, approximately 20 h was required for
the peak at 21.5 min to convert to the peak at 19.7 min in the wild-
type PrP samples (Fig. 1A and B). The reaction of Met oxidation to
Met-sulfoxide transforms the methionine sulfur atom into sulfoxide
groups causing an increase in the side chain hydrophilicity [21,22,29].
Due to the relatively higher surface hydrophilicity, the Met oxidized
protein can be eluted at a lower concentration of acetonitrile, which re-
sults in a time-dependent shift in the reverse-phase HPLC mobility of
Fig. 1. Oxidation of the D178N variant and wild-type huPrP by hydrogen peroxide, as monitored using C8 reverse-phase HPLC. An aliquot of wild-type huPrP (A) and the D178N variant
(B) fromeach reactionwas subjected to C8 reverse-phase HPLC to separate the oxidized forms. Integrationwas performed onpeaks A (white bar with slash), B (gray barwith slash), and C
(black bar with slash) of wild-type huPrP (C) and the D178N variant (D) for each H2O2 treated time.
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may correspond to different degrees of oxidation of PrP.
Quantitation of the peaks in Fig. 1A and B by integration of absor-
bance illustrates the transition from the A to the B to the C forms with
increasing oxidation time. As shown in Fig. 1C and D, after incubation
with H2O2 for 1 h, the D178N variant was almost fully converted to
the partially oxidized form (B peak), whereas approximate 40% of
wild-type huPrP remained in unoxidized form (A peak). After incuba-
tion with H2O2 for 8 h, the D178N variant was almost converted to the
ﬁnal oxidized form (C peak), whereas a fraction of wild-type huPrP
remained in a partially oxidized form (B peak) even after treatment
for 20 h. These results provide evidence that the D178N variant was
more susceptible to oxidation than wild-type huPrP (Fig. 1C and D).
3.2. Mass spectrometry
3.2.1. MALDI-TOF MS analysis
Next, matrix-assisted laser desorption/ionization time-of-ﬂight MS
was used to examine the oxidized forms of the D178N PrP variant and
wild-type PrP. As shown in Fig. 2, the measured mass of the D178N
PrP variant was 22,968.2 Da (calculated mass of 22,964.3 Da). After ox-
idation for 1 h, themeasuredmass of D178NPrPwas 23,074.3 Da,which
was 106.1 Da larger than that for unoxidized D178N, corresponding to
the oxidation of approximately 7 Met residues (calculated mass of
23,076.3 Da). After incubation for an additional 7 h, the m/z observed
for the highest peak for oxidized D178N PrPwas 23,119.2 Da, indicating
that in most of the D178N PrP molecules, approximately 10 Met resi-
dues had been oxidized to Met-sulfoxide (calculated mass of
23,124.3 Da). In other words, all Met residues (including the ﬁrst Met,which was not removed due to prokaryotic expression [30]) had been
oxidized during the 8-h oxidation. As shown in Fig. 2, the oxidation of
approximately 6Met residues ofwild-type PrP took about 2 h (themea-
sured mass was 93.8 Da larger than that for unoxidized wild-type PrP),
whichwas comparablewith D178NPrP. However, in contrast to the rel-
atively short oxidation time required for D178N (approximately 8 h),
the oxidation of all Met residues in wild-type PrP took more than 20 h
which was much longer.
3.2.2. Mapping Met oxidation by LC-ESI-MS
After tryptic digestion and desalting, the peptide mixture was con-
ﬁrmed by high-resolution mass analysis using nano-ESI-based LC–MS/
MS. The 9 Met residues of D178N PrP and wild-type are distributed on
6 tryptic fragments, 2 of them with more than one Met residue. These
are HMAGAAAAGAVVGGLGGYMLGSAMSR (Met-112/129/134) and
MMER (Met-205/206). The overall patterns of the H2O2 induced Met
oxidation in all analyzed peptides of D178N variant and wild-type PrP
were presented in Fig. 2D and H, respectively. Expectedly, after treat-
ment of D178N PrP variant with H2O2 for 1 h and of wild-type PrP for
2 h, almost 4 tryptic fragments with Met-109, Met-112/129/134, Met-
154, Met-166 were fully oxidized, whereas 2 tryptic fragments with
Met-205/M206,Met-213were almost unoxidized.Moreover, after incu-
bation with H2O2 for 8 h, all 9 Met residues of the D178N variant were
almost oxidized, and that took 20 h for wild-type PrP. These ﬁndings
conﬁrm that the 6 surface-exposed Met residues of both D178N PrP
and wild-type PrP variant were susceptible to oxidation in the partially
oxidized form, and then after incubation for an additional 7 h for D178N
PrP and 18 h for wild-type PrP, respectively, the buried Met-205/206
and partially surface-exposed Met-213 residues were further oxidized.
Fig. 2.MALDI-TOF mass spectra of the D178N variant (A), the D178N variant oxidized for 1 h (B), and the D178N variant oxidized for 8 h (C). The extent of Met oxidation of the D178N
variant was evaluated from the integrated peak area by LC-ESI-MS: (bar 1) unoxidized, (bar 2) oxidized for 1 h, and (bar 3) oxidized for 8 h (D). MALDI-TOFmass spectra of thewild-type
PrP (E), thewild-type PrP oxidized for 2 h (F), and thewild-type PrP oxidized for 20 h (G). The extent ofMet oxidation of thewild-type PrPwas evaluated from the integrated peak area by
LC-ESI-MS: (bar 1) unoxidized, (bar 2) oxidized for 2 h, and (bar 3) oxidized for 20 h (H).
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structure and decreases the thermal stability of PrP
CD spectroscopy was used to investigate secondary structural
changes in the oxidized forms of wild-type huPrP and the D178N vari-
ant. Fig. 3A and B present the CD spectra of oxidized and unoxidized
PrP samples. The far-UV CD spectra of the unoxidized forms of the two
proteins are characteristic ofα-helical structure, exhibiting double neg-
ative peaks at 222 and 208 nm (Fig. 3A and B). Oxidation of the wild-
type and D178N PrP for short times did not alter their secondary struc-
ture (Fig. 3A and B). However, oxidation of D178N PrP for longer time
(8 h for D178N) resulted in a single minimum at approximately
215 nm, which is typical of a predominantly β-sheet conformation
(Fig. 3B), whereas the secondary structure of wild-type did not alter
when oxidized for the identical time (8 h for wild-type) (Fig. 3A).
DSC and thermal unfolding CDwere used to compare the thermody-
namic stability of oxidized and unoxidized forms of wild-type huPrP
and the D178N variant (Fig. 3C and D). The Tm value of wild-type PrP
measured using DSC was 61.0 °C, which was signiﬁcantly higher than
that of the D178N variant (53.9 °C). However, after oxidation for shorttimes, the Tm value of wild-type PrP decreased to 57.5 °C, whereas
that of the D178N variant further decreased to 51.0 °C (Fig. 3D). When
ﬁtted to a sigmoid model, the thermal unfolding curves recorded by
CD exhibited a trend in stability that was identical to the results obtain-
ed from DSC analysis. These results indicate that D178N was less stable
than wild-type PrP and that oxidation further decreased the stability of
D178N,whichmay explain the greater sensitivity of D178N to oxidation
thanwild-type huPrP. In addition, the short oxidative treatment did not
notably alter the overall structure of PrP. In contrast, the oxidation of all
of the Met residues signiﬁcantly affects the conformation of PrP.
3.4. The oxidized D178N variant exhibits more signiﬁcant aggregation in
comparison to wild-type huPrP
The formation of oligomers and higher-order aggregates of oxidized
wild-type huPrP and the D178N variant was analyzed using SDS-PAGE.
SDS-PAGE using precast 4–12% NuPAGE gradient gels has previously
been used to assess the formation of oligomers [31–33]. Coomassie Bril-
liant Blue staining of PrP samples after separation in 4–12%NuPAGE gels
demonstrated the assembly of some SDS-resistant dimers and high-
Fig. 3. Secondary structure and stability analysis of oxidizedwild-type huPrP and theD178Nvariant, asmeasured by CDandDSC. (A) Secondary structure ofwild-type huPrP (black curve),
wild-type huPrP after oxidation for 1 h (blue curve) and 8 h (red curve). (B) Secondary structure of D178N variant (black curve), D178N variant after oxidation for 1 h (blue curve) and 8 h
(red curve). (C) Thermal denaturing curves recorded at 222 nm of wild-type huPrP (solid triangles), wild-type huPrP oxidized for 2 h (solid circles), the D178N variant (open triangles),
and the D178N variant oxidized for 1 h (open circles). (D) Thermal denaturation scans of wild-type huPrP (curve 1), wild-type huPrP oxidized for 2 h (curve 2), the D178N variant (curve
3), and the D178N variant oxidized for 1 h (curve 4) recorded using DSC in phosphate buffer, pH 6.0. The heating rate during the scan was 1 °C/min. Excess molar heat capacity is repre-
sented as a function of the temperature. Experimental traces (continuous lines) and theoretical ﬁts (dashed lines) are shown.
2350 B. Feng et al. / Biochimica et Biophysica Acta 1842 (2014) 2345–2356molecular-weight aggregates under extended oxidation times. The
long-exposure gels for dimers and high-molecular-weight aggregates
bands are shown. After oxidation for 2 h, clear dimer and high-
molecular-weight aggregates bands were formed in the D178N sample
(Fig. 4A). However, the wild-type PrP remained in the monomeric state
until oxidation for 4 h. Notably, D178N after incubation with H2O2
formed a greater amount of aggregates more rapidly than wild-type
huPrP, indicating thatmethionine oxidation accelerated the aggregation
of the D178N variant.
To quantify the higher-order aggregates and dimers formed at ex-
tended oxidation times, relative integrated peak area were normalized
to percentage when the values of higher-order aggregates and dimers
of D178N PrP formed at 8 h were set as 100%, respectively. We found
that the SDS-resistant high-molecular-weight aggregates formed in
the D178N sample were approximately twice as much as wild-type
huPrP under the identical oxidation times, and the dimers formed
were more than two times of wild-type huPrP (Fig. 4B). The high-
molecular-weight aggregates and dimers formed may serve as the
seeds and induce the further PrP misfolding and neurotoxicity.
The enhanced ﬂuorescence emission of ThT has frequently been
used to detect the oligomerization and aggregation of amyloidogenic
proteins and is a speciﬁc marker for β-sheet-rich structures. Here, we
utilized the ThT binding assay to monitor the aggregation propensity
(Fig. 4C). We found that the ThT ﬂuorescence intensity of D178N PrP
samples wasmuch higher than that of wild-type PrP under identical in-
cubation times (Fig. 4C). Moreover, the ThT ﬂuorescence intensity ofD178N PrP notably increased more rapidly than that of wild-type PrP.
Taken together, this result suggests that the assembly of D178N into di-
mers and larger aggregates is more signiﬁcant than that of wild-type
huPrP.
ANS has frequently been used as a polarity-sensitive ﬂuorescent
probe. In this study, we used ANS binding assay to compare the hydro-
phobic surface ofwild-type huPrP and theD178Nvariant under extend-
ed oxidation times (Fig. 4D). We found that the ANS ﬂuorescence
intensity of D178N PrP samples was much higher than that of wild-
type PrP under identical incubation times (Fig. 4D). This result suggests
that hydrophobic surface exposure of D178N variant is more obvious
than that of wild-type huPrP, and then makes it more susceptible to
aggregate.
3.5. Oxidized forms of the D178N variant exhibit increased PK resistance in
comparison to oxidized wild-type huPrP
PK resistance has been regarded as a key hallmark of pathological
forms of PrP that possess an abnormal conformation. Oxidized wild-
type huPrP and D178N huPrP were digested using various concentra-
tions of PK. As shown in Fig. 5, unoxidized D178N and wild-type PrP
were both sensitive to PK digestion. The D178N andwild-type PrP sam-
ples that were oxidized for short times exhibited a slight increase in PK
resistance, and D178N exhibited more resistance to PK digestion. How-
ever, increased oxidation of D178N resulted in PK-resistant bands even
at a PK:rPrP molar ratio of 1:50. In contrast, oxidized wild-type PrP
Fig. 4. Time-dependent aggregation assays of wild-type huPrP and theD178N variant during oxidation. (A) A Bis-Tris SDS-PAGE system using precast NuPAGE gradient gels to analyze PrP
aggregation. Samples were incubated with 50 mM H2O2 at 37 °C. A portion of the samples collected at the indicated time points was mixed with LDS sample buffer in the absence of re-
ducing agent. Each lane was loaded with 10 μg of protein sample. The gels were stained using Coomassie Blue. Higher-order aggregates appear at the top of the running gels. The long-
exposure gels for dimers and high-molecular-weight aggregates bands are shown.Molecularmarkers (in kDa) are shown (left). (B) Quantiﬁcation of higher-order aggregates and dimers
formed at extended oxidation times. The integrated peak area is simply the band area and gray value of higher-order aggregates and dimers at extended oxidation times multiplied to-
gether, relative integrated peak area were normalized to percentage when the values of higher-order aggregates and dimers of D178N PrP formed at 8 h were set as 100%, respectively.
(C) Thioﬂavin T (ThT) ﬂuorescence assay of wild-type and D178N PrP at extended oxidation times. The data represent the emission peak at 488 nmas a function of incubation time. (D) 8-
Anilino-1-naphthalen- sulfonic acid (ANS) ﬂuorescence assay of wild-type and D178N PrP at extended oxidation times.
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(8 h), and the bands of oxidizedwild-type PrP became faint at a PK:rPrP
molar ratio of 1:100. These results suggest that oxidized wild-type
huPrP and oxidized D178N exhibited partial resistance to PK digestion,
but increased oxidation of the D178N variant rendered it more resistant
to PK digestion.
3.6. Aggregation and PK resistance of wild-type huPrP and the D178N
variant after oxidation in N2a cells
To investigate the aggregation of wild-type PrP and the D178N var-
iant in cells under oxidative stress, we transiently transfected RFP-fused
wild-type and D178N PrP into Neuro-2a cells (N2a) and examined the
generation of aggregates in cells treated with H2O2. RFP fusion was
used to visualize the subcellular distribution and the extent of aggrega-
tion of these proteins. As shown in Fig. 6, wild-type PrP was primarily
localized at the plasma membrane when expressed in N2a cells
(Fig. 6A, red); in contrast, D178N was primarily retained in the cyto-
plasm and partially formed aggregates (Fig. 6C, red). After treatment
withH2O2, a fraction ofwild-type PrP failed to be secreted, and some ag-
gregates were found in the cytoplasm (Fig. 6B, red). Notably, when
expressed in the cells, the D178N variant generated a large number of
aggregates, which were deposited as brightly ﬂuorescent punctate
dots upon treatment with H2O2 (Fig. 6D, red).Subsequently, we performed double-ﬂuorescence labelingwith ThS,
which is speciﬁc for β-sheet-rich structures, to determine the structural
characteristics of the aggregates (Fig. 6A–D). ThS ﬂuorescence was de-
tected using confocal microscopy and indicated the presence of green
puncta of ThS, which were associated with red RFP in N2a cells that
had been transfected with D178N and treated with H2O2 (Fig. 6D). In
contrast, fewer puncta (Fig. 6C) were found in cells transfected with
D178N alone (Fig. 6C). In cells that were transfected with wild-type
PrP followed by oxidative treatment, few puncta were observed
(Fig. 6B); in the absence of oxidative treatment, diffuse background
ﬂuorescence was observed (Fig. 6A). The arrows indicate PrP (red)
that was colabeled with ThS (green) (Fig. 6B–D).
We further investigate the aggregation states of wild-type PrP and
theD178N variant in cells afterH2O2 treatment using SDD-AGE analysis.
This technique has foundwidespread use in the study of both prion and
non-prion SDS-resistant aggregates [28,34–36]. As shown in Fig. 6E, the
oxidative treatment of N2a cells induced minor aggregation of wild-
type PrP but resulted in profoundly more abundant aggregates of
expressed D178N. Moreover, this event was accompanied by a gradual
decrease in the amount of monomeric protein (Fig. 6E). We also evalu-
ated the PK resistance of samples corresponding to the aggregates
shown in Fig. 6E. As shown in Fig. 6F, wild-type PrP was sensitive to
PK digestion when expressed in N2a cells and was completely digested
upon exposure to 2 μg/ml PK. Aggregates of wild-type PrP that were
Fig. 5. Concentration-dependent proteinaseK digestion assays ofwild-type huPrP oxidized for 0 h (A), 1 h (B), and 8 h (C) and of theD178N variant oxidized for 0 h (D), 1 h (E), and 8h (F).
Protein samples oxidized for the indicated timeswere incubated at various PK:PrPmolar ratios (1:5000–1:50) for 1 h at 37 °C andwere then resolvedusing 15% SDS-PAGE and detected by
Coomassie Blue staining.
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dative treatment enhanced the PK resistance of aggregates of D178N
upon expression in N2a cells and generated a clearly PK-resistant core
with a mass of approximately 27–30 kDa.3.7. Oxidation of the D178N variant enhances cell apoptosis
Cell apoptosis wasmonitored by assessing annexin V and propidium
iodide-positive cells using ﬂow cytometry. As shown in Fig. 7A and D,
after treatment with 50 μM H2O2, the number of early apoptotic cells
in a population of cells that had been transiently transfected with the
empty vector pcDNA3.1 marginally increased from approximately
9.6% to 15.2%. The percentage of early apoptotic cells in a population
of cells that had been transiently transfected with wild-type huPrP1-
253 increased from approximately 10.1% to 18.0% after treatment
(Fig. 7B and E). However, treatment of D178N huPrP1-253-transfected
cells with 50 μM H2O2 signiﬁcantly increased the number of early apo-
ptotic cells to 26.5% (Fig. 7C and F). Cells transfected with the D178N
huPrP1-253 variant exhibited an increase in the number of cells in late
apoptosis and necrosis from 3.2% to 7.4%, whereas wild-type huPrP1-
253 under an identical oxidative treatment only exhibited an increase
in the number of cells in late apoptosis and necrosis of 0.3% (from 3.5%
to 3.8%). As depicted in Fig. 7G and H, after treatment with 50 μM
H2O2, total apoptosis rate for cells transfected with the D178N
huPrP1-253 increased from approximately 23.3% to 37.5%, whereas
wild-type huPrP1-253 under an identical oxidative treatment only ex-
hibited an increase in the apoptosis rate of 6.7% (from 14.3% to 21%).
These results strongly suggest that oxidation of the D178N variant and
subsequent aggregation induced more pronounced apoptosis of N2a
cells.4. Discussion
The mechanism by which the largely α-helical normal PrPC is con-
verted into an infectious PrPSc isoform remains unclear and is a topic
of interest within the ﬁeld of prion research.Wehave noted that protein
conformational diseases such as Alzheimer's disease (AD) and
Parkinson's disease (PD) primarily exhibit old-age onset, and their inci-
dence increases with advancing age. These characteristics suggest that a
cascade of events occurs with aging that induces a disease-speciﬁc pro-
tein conformational change. Numerous studies have described the asso-
ciation between the pathogenicity of these neurodegenerative disorders
and oxidative stress [12–15,17]. Oxidative stress is also a crucial feature
of the pathogenesis of prion disease, and increasing evidence supports a
causal link between oxidative stress and prion diseases [37–41]. The
huPrP sequence contains nine methionine residues, six of which are
surface-exposed (Met109, Met112, Met129, Met134, Met154, and
M166); Met205 and Met206 are buried, and M213 is partially surface-
exposed [20,21,42]. Our ﬁndings by the RP-HPLC and MS analysis con-
ﬁrm that Met205, Met206 and Met213, which require more time to be
fully oxidized, are less accessible to oxidants compared with other 6
Met residues. This result agrees with previous reports from other labo-
ratories [20,22]. However, the oxidation of surface exposed 6 Met resi-
dues would destabilize the PrP and open the buried hydrophobic area
of Met205, Met 206 and Met213. Hence, these buried Met residues
could be accessed and oxidized. It is worth noting that the oxidation
of surface-exposed Met residues does not alter the overall structure of
PrP, but the oxidation of M206 and M213 signiﬁcantly affects the con-
formation. These results suggest that the surface-exposed Met residues
may represent a natural defense mechanism for PrP against oxidation,
andmethionine sulfoxide reductase A (MsrA) can repair proteins by re-
ducing methionine sulfoxide [43,44]. However, the oxidation of buried
Fig. 6. Aggregation of wild-type huPrP and the D178N variant in N2a cells after oxidative treatment and assessment of PK resistance. N2a cells were transfected with wild-type huPrP
(A and B) or D178N-variant (C and D) plasmids; 24 h posttransfection, the cells were treated (B and D) or not treated (A and C) with 50 μM H2O2 for an additional 12 h. A–D show the
epiﬂuorescence microscopy of aggregates formed in cells after staining with thioﬂavin S (ThS). Speciﬁc thioﬂavin S-positive puncta in cells are indicated. Scale bars represent 10 μm.
The arrows indicate ThS (green)-positive aggregates that colocalized with RFP-fused PrP (red). (E) Aggregates generated in N2a cells expressing wild-type and D178N huPrP were ana-
lyzed using SDD-AGEwith orwithout H2O2 treatment as described in the “Materials andmethods” section. (F) N2a cells were transiently transfectedwithwild-type huPrP and theD178N
variant and were then treated or not treated with 50 μM H2O2 for an additional 12 h. The total cell lysates were incubated with or without 2 μg/ml PK as indicated for 30 min at 37 °C.
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by inducing irreversible aggregation, which is consistent with previous
studies [21,45,46]. In the present case, though the oxidation of the 6
surface-exposed Met residues takes a short time (1–2 h) for both
D178N and wild-type PrP, the further oxidation of all the Met residues
of D178N variant requires about an additional 7 h comparison to more
than 18 h for wild-type PrP. The longer oxidation time required for
wild-type PrP means relatively more chances for the reversible reduc-
tion ofMet sulfoxide bymethionine sulfoxide reductase (Msr) to reduc-
ing methionine sulfoxide. In contrast, the oxidation of D178N PrP
requires much shorter time and accompanied with the more extent of
aggregation formation. Together with the less stability of D178N vari-
ant, it is not difﬁcult to understand that D178N variant is more suscep-
tible to methionine oxidation than wild-type huPrP, and the oxidation
accelerates the aggregation and enhances the neurotoxicity of the
D178N variant in vitro and in cell.
Methionine oxidation is a general feature of aging [47–49]. Oxidative
stress is also an important feature of neurodegenerative diseases includ-
ing prion diseases [50]. Inherited prion diseases always exhibit earlier
onset (mean age of 51 years for D178N-associated FFI) than sporadic
prion diseases. Therefore, methionine oxidation may play an important
role in the pathogenesis of FFI. Recently, several studies have demon-
strated that methionine oxidation may trigger a structural destabiliza-
tion of the cellular isoform of PrP, possibly representing the initial
event of the conversion pathway [20,46,51]. Most pathogenicmutations
rarely alter the native structure of PrPC but rather perturb its stability,
regulate oligomerization pathways, and determine the features ofPrPSc assemblies [52–58]. Based on our results and those of recent stud-
ies [21,45,59,60], we propose a hypothesis relating methionine oxida-
tion to the pathogenesis of the D178N variant. NMR studies have
shown that Asp178 of PrP forms hydrogen bonds with Arg164 and
Tyr128 [42]; the Asp178 to Gln mutation examined here may disrupt
this hydrogen-bonding network, subsequently rendering the buried
Met residues susceptible to oxidation. Thus, it is not surprising that
the D178N variant is more susceptible to oxidation. Moreover, PrP acts
as an important neuroprotective factor; when mutated to D178N, the
protein fails to transport to the cell membrane and loses its antioxidant
function, forming aggregates as indicated in Fig. 6. The D178N variant
itself could therefore be a target of oxidative damage. Subsequent
oxidation of D178N PrP further enhances the structural conversion,
generating a large amount of aggregation in neuronal cells. These results
provide useful clues to understand the earlier onset of D178N-
associated FFI diseases. It has been reported that reactive oxygen species
(ROS)mightmediateβ-cleavage of PrP [16,61–63], but therewas nono-
table β-cleavage observed in our study. In the β-cleavage experiments
studied in these reports, PrP samples were treated with H2O2 and cop-
per or other metal ion together, the generation of ROS is promoted by
the presence of copper and iron through the Fenton reaction [61,64].
The oxidantH2O2, whichwas used alone in the present study, canmain-
ly oxidize Met residues to methionine sulfoxide [22]. The oxidation of
His or Tyr residues by hydroxyl radicals and other ROS may also affect
PrP misfolding and neurotoxicity [65–68].
We found that oxidation also promoted the conversion of wild-type
PrP to a misfolded form to some degree, which may account for the
Fig. 7. Cell apoptosiswasmonitored by ﬂow cytometry detected using annexin V/PI staining. N2a cells were transfectedwith pcDNA3.1 (A and D), wild-type huPrP (B and E), and D178N-
variant huPrP (C and F) plasmids; 24 h posttransfection, the cellswere treatedwith 0 μM(A, B, and C) and50 μMH2O2 (D, E, and F) for 12h. The x-axis represents theﬂuorescence intensity
of FITC. The y-axis represents the ﬂuorescence intensity of propidium iodide. Q4 denotes early apoptosis, Q2 denotes late apoptosis and necrosis, and Q3 denotes normal cells. The per-
centage of the overall population in each quadrant is provided in the corner. Bar graph of cell apoptosis without H2O2 treated (G) and with 50 μM H2O2 treated (H). Results of early
and late apoptosis were added together to calculate the total amount of apoptosis. The data shown represented themean values and standard deviations of the results. The statistical sig-
niﬁcance of differences in the cell apoptosis between wild-type and the D178N variant was calculated by t-test. **: P b 0.01. Three independent replicates were performed.
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lated oxidative stress in old age, possibly revealing that oxidative stress
also plays a role in the pathogenesis of sporadic prion diseases.
The M129V polymorphismwithin the PRNP gene results in not only
the different pathological phenotypes but also the misfolding propensi-
ty of PrP [11,69–71]. FFI and 178CJD, shared the D178Nmutation in the
PrP gene but had distinct phenotypes linked to codon 129, the site of a
methionine–valine polymorphism: FFI linked to D178N mutation hap-
lotype with a methionine at codon 129, 178CJD linked to D178N muta-
tion haplotype with a valine at codon 129 [11,71]. Additionally,
homozygosity or heterozygosity for methionine at codon 129 has been
thought to inﬂuence the progression of FFI [9,69,72], which is still an un-
solved issue.
Initially, we hypothesized that the substitution of Met129 to Val,
which cannot be oxidized, might contribute to the observed neuropath-
ological differences between D178N/M129 associated FFI and D178N/
M129V associated CJD. In the present study, the D178N/M129V variant
of PrP exhibited a slightly reduced susceptibility to oxidation, approxi-
mately 12 h (4 h longer than D178N but 8 h shorter than wild-type
PrP) was required for the unoxidized D178N/M129V PrP convert to
fully oxidized form (Fig. S1). In addition, the D178N/M129V variant
PrP was also signiﬁcantly destabilized by oxidation compared with
wild-type PrP, the Tm value of D178N/M129V variant and D178N/
M129V variant oxidized for short times were 54.8 °C and 52.1 °C, re-
spectively (Fig. S2). Moreover, the oxidized form of the D178N/M129V
variant also exhibited a propensity to form β-sheet-rich aggregates.Met oxidation did not result in signiﬁcant differences in the aggregation
between the D178N and D178N/M129V variants (Fig. S3).
Methionine oxidation has also been implicated in AD and PD patho-
genesis in the past decade, and studies have shown a strong correlation
between the level of ROS and pathogenicity [15,73–75]. The oxidized
form of amyloidogenic proteins including amyloid beta (Aβ), α-
synuclein, and the prion protein have been reported to play a special
role in AD, PD, and prion diseases, respectively [75–77]. Met-oxidation
has been reported to stabilize oligomeric forms of α-synuclein, which
may be more cytotoxic [15]. However, Met35 oxidation has been sup-
posed to inhibit the ﬁbril assembly of Aβ1-40 [75,78]. For the ﬁrst
time, our study establishes a direct link between methionine oxidation
and the FFI-associated D178N variant.
In conclusion, Met oxidation destabilizes the native conformation,
accelerates aggregation, and enhances the neurotoxicity of the D178N
PrP variant. Our results highlight the relationship between methionine
oxidation and pathogenic mutations in prion diseases andmay advance
our understanding of the pathogenesis of other protein conformational
diseases such as AD and PD.Author contributions
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